

Discovery of drug mode of action and drug repositioning from transcriptional responses

Francesco Iorio^{a,b}, Roberta Bosotti^c, Emanuela Scacheri^c, Vincenzo Belcastro^a, Pratibha Mithbaokar^a, Rosa Ferriero^a, Loredana Murino^b, Roberto Tagliaferri^b, Nicola Brunetti-Pierri^{a,d}, Antonella Isacchi^{c,1}, and Diego di Bernardo^{a,e,1}

^aTelethon Institute of Genetics and Medicine, Naples, Italy; ^bDepartment of Biotechnology, Nerviano Medical Sciences, Milan, Italy; ^cDepartment of Systems and Computer Science, "Federico II" University of Naples, Naples, Italy; ^dDepartment of Pediatrics, "Federico II" University of Naples, Naples, Italy; and ^eDepartment of Mathematics and Computer Science, University of Salerno, Salerno, Italy

Edited by Charles R. Cantor, Sequenom, Inc., San Diego, CA, and approved July 2, 2010 (received for review January 5, 2010)

A bottleneck in drug discovery is the identification of the molecular targets of a compound (mode of action, MoA) and of its off-target effects. Previous approaches to elucidate drug MoA include analysis of chemical structures, transcriptional responses following treatment, and text mining. Methods based on transcriptional responses require the least amount of information and can be quickly applied to new compounds. Available methods are inefficient and are not able to support network pharmacology. We developed an automatic and robust approach that exploits similarity in gene expression profiles following drug treatment, across multiple cell lines and dosages, to predict similarities in drug effect and MoA. We constructed a "drug network" of 1,302 nodes (drugs) and 41,047 edges (indicating similarities between pair of drugs). We applied network theory, partitioning drugs into groups of densely interconnected nodes (i.e., communities). These communities are significantly enriched for compounds with similar MoA, or acting on the same pathway, and can be used to identify the compound-targeted biological pathways. New compounds can be integrated into the network to predict their therapeutic and off-target effects. Using this network, we correctly predicted the MoA for nine anticancer compounds, and we were able to discover an unreported effect for a well-known drug. We verified an unexpected similarity between cyclin-dependent kinase 2 inhibitors and Topoisomerase inhibitors. We discovered that *Fasudil* (a Rho-kinase inhibitor) might be "repositioned" as an enhancer of cellular autophagy, potentially applicable to several neurodegenerative disorders. Our approach was implemented in a tool (Mode of Action by NeTwork Analysis, MANTRA, <http://mantra.tigem.it>).

computational drug discovery | drug repurposing | systems biology | chemotherapy

Identifying molecular pathways targeted by a compound (drug effects), and the specific compound-substrate interactions (drug mode of action—MoA), is of paramount importance for the development of new drugs, and also for new clinical applications of already existing drugs (1–3). Systems biology approaches are naturally suited to capture the complexity of drug activity in cells (4–6). Prediction of drug MoA has been attempted by using gene expression profiles following drug treatment (7–13), by comparing side-effect similarities (14), by text-mining literature (15), or by applying chemoinformatic tools to search for small molecules similarities (16, 17). Most of these approaches are applicable only to well-characterized molecules (e.g., when the structure is available, or side effects are documented). On the other hand, expression profile-based methods are the most general ones, because they do not require any prior information on the compound being analyzed. Among the most promising approaches are the ones based on "gene signatures" (11, 12), i.e., subset of genes whose differential expression can be used as a marker of the activity of a given pathway, disease or compound. Gene signatures can be used to discover "connections" among drugs, pathways, and diseases (8, 11, 12, 18) using a large collection of transcriptional responses following compound treatments, such as the "Connec-

tivity Map" (11, 12). These compound-specific expression profiles can be queried with a gene signature to recover a subset of compounds connected to the signature of interest. A compound is selected if genes in the signature are significantly modulated in the compound-specific transcriptional response. If a gene signature for a new compound is available, it is then possible to search the collection of transcriptional responses with that signature to identify well-characterized drugs, which behave similarly, and thus infer the MoA of the new compound. The problems affecting gene signature-based methods are in the choice of the subset of genes composing the signature, and in the proper handling of multiple expression profiles obtained by treating different cell lines, with the same compound. A wrong selection of genes in the signature will lead to capture similarities in the experimental settings (i.e., same cell line) rather than in the drug MoAs (*SI Methods*). Because of these limitations, the analysis of the transcriptional response to a new compound is usually performed by mapping the most differentially expressed genes, following compound treatment, onto known biological pathways, in order to detect the most perturbed pathways. Such attempts are met with limited success due to the complexity of "backtracking" expression changes to primary causes (i.e., molecular targets).

Inspired by these considerations, we developed a general approach, with a matched online tool, to identify and classify the pathway targeted by a compound and its MoA. We computed for each drug a "consensus" synthetic transcriptional response summarizing the transcriptional effect of the drug across multiple treatments on different cell lines and/or at different dosages. We then constructed a "drug network" (DN) in which two drugs are connected to each other if their consensus responses are similar according to a similarity measure that we developed (drug distance). We divided the DN into interconnected modules termed "communities" and "rich clubs" (19). By analyzing these modules, we were able to capture similarities and differences in pharmacological effects and MoAs; we were able to predict MoA of anticancer compounds still being studied and to discover previously unreported MoAs for well-known drugs.

We developed a Web-based tool to explore the DN and query it for classification of previously undescribed compounds (Mode of Action by Network Analysis—MANTRA, <http://mantra.tigem.it>).

Author contributions: F.I., N.B.-P., A.I., and D.d.B. designed research; F.I., R.B., E.S., P.M., N.B.-P., A.I., and D.d.B. performed research; F.I., V.B., and R.T. contributed new reagents/analytic tools; F.I., R.B., E.S., V.B., P.M., R.F., L.M., A.I., and D.d.B. analyzed data; and F.I., R.B., E.S., N.B.-P., A.I., and D.d.B. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The microarray data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE18552).

¹To whom correspondence may be addressed. E-mail: antonella.isacchi@nervianoms.com or dibernardo@tigem.it.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1000138107/-DCSupplemental and at <http://mantra.tigem.it>.

Results

Drug Network and Communities. We quantified the degree of similarity in the transcriptional responses among drugs. To this end, we exploited a repository of transcriptional responses to compounds: the Connectivity Map (cMap) (11, 12) containing 6,100 genome-wide expression profiles obtained by treatment of five different human cell lines at different dosages with a set of 1,309 different molecules. We represented the similarity between two drugs as a “distance” and computed it as summarized in Fig. 1A: For each compound, we considered all the transcriptional responses following treatments, across different cell lines and/or at different concentrations. Each transcriptional response was represented as a list of genes ranked according to their differential expression. We then computed a single “synthetic” ranked list of genes, the Prototype Ranked List (PRL), by merging all the ranked lists referring to the same compound. In order to equally weight the contribution of each of the cell lines to the drug PRL, rank merging was achieved with a procedure (detailed in *SI Methods*) based on a hierarchical majority-voting scheme, where genes consistently overexpressed/down-regulated across the ranked lists are moved at the top/bottom of the PRL (18). The rank-merging procedure first compares, pairwise, the ranked lists obtained with the same drug using the Spearman’s Footrule similarity measure (20). Then, it merges the two lists that are the most similar to each other, following the Borda Merging Method (21), thus obtaining a single ranked list. This new ranked list replaces the two lists, and then the procedure is repeated until only one ranked list remains (the PRL of the drug). The PRL thus captures the consensus transcriptional response of a compound across different experimental settings, consistently reducing non-relevant effects due to toxicity, dosage, and cell line (*SI Methods*).

The distance between a pair of compounds is computed by comparing the two PRLs. To this end, we extracted an “optimal” gene signature for each of the two compounds by selecting the first 250 genes at the top of the PRL (most overexpressed) and the last 250 genes at the bottom of the PRL (most down-

regulated). The size of these optimal signatures was heuristically determined as described in *SI Methods*.

We then checked if the genes in the optimal gene signature of the first compound ranked consistently at the top/bottom of the PRL of the second compound, and vice versa, using the Gene Set Enrichment Analysis (GSEA) (22). We computed the GSEA enrichment score of the optimal gene signature of compound A in the PRL of compound B, and vice versa. We then combined the two scores to obtain a single value quantifying the distance between compound A and B (*SI Methods*). The smaller the distance, the more similar the two compounds are. We computed the distance for each pair of the 1,309 compounds in the cMap dataset for a total of 856,086 pairwise comparisons. We then considered each compound as a node in a network and connected two nodes with a weighted edge (where the weight is proportional to their distance), if their distance was below a significant threshold value (Fig. 1B). Drugs that were not connected to any other compound by at least one edge were excluded from the DN (*SI Methods*).

The resulting DN has a giant connected component with 1,302 nodes (i.e., drugs) out of 1,309 and 41,047 edges, corresponding to 5% of a fully connected network with the same number of nodes (856,086 edges). In order to analyze and visualize the DN, we identified its communities via a recent clustering algorithm (23) (*SI Methods* and Fig. 1B). A community is defined as a group of nodes densely interconnected with each other and with fewer connections to nodes outside the group (24). As shown in Fig. 2, we identified 106 communities [online Supporting Information (SI) at <http://mantra.tigem.it>]. Each community was coded with a numerical identifier, a color, and one of its nodes was identified as the “exemplar” of the community, i.e., the drug whose effect best represents the effects of the other drugs in the community. We assessed that the tendency of our method to group drugs in the same community was not due to trivial chemical commonalities (*SI Methods*).

We next determined whether drugs within a community shared a common MoA. We collected for each drug the Anatomical Therapeutic Chemical (ATC) code, the known direct target




Fig. 1. Methodology overview. (A) A distance value for each couple of drugs is computed. (B) Each drug is considered as a node in a network with weighted edges (proportional to distances) connecting pairs of drugs. Network communities are identified. (C) Ranked list of differentially expressed genes, following treatment with a previously undescribed drug X are merged together, and the distance $d(X,Y)$ is computed for each drug Y in the reference dataset. X is connected to drugs whose distance is below a significant threshold.




Fig. 2. The Drug network. Communities and rich clubs are highlighted. (Insets) Some communities are magnified, and the enriched Mode of Actions are provided.

genes, and other literature-based evidences. ATC codes (25, 26) are alphanumeric strings assigned by the World Health Organization to group drugs according to their therapeutic and chemical profiles. ATC codes were available for 59% of the drugs (768 out of 1,309). We retrieved the known target genes for 535 out of 1,309 (41%) drugs from two public repositories, DrugBank (27) and ChemBank (28). We thus assigned a known MoA to 804 drugs out of 1,309 (61%) (Dataset S1). For each community, we counted the number of drugs with the same MoA. We then divided this number by the number one would expect had the drugs been randomly grouped, to compute “odds ratios” and p values (SI Methods). We found that 52 out of 95 assessable communities (i.e., those containing at least two compounds with known MoA) were significantly enriched (p value < 0.05) for compounds with similar MoA. Specifically, 3 communities were enriched for a direct target gene, 28 for one ATC code, whereas 21 were enriched for both a direct target gene and an ATC code. Additionally, by searching the literature for supporting evidences, we found 43 communities including several compounds with similar MoA, 9 of which were composed by compounds with no ATC codes and no known target genes. So the total number of enriched communities was 61 (52 + 9) (Fig. S1). This number goes up to 77, considering as significant communities, those with a corresponding significant odds ratio greater than 1 (SI Methods).

We further checked if compounds in the same community impacting on common biological pathways. We developed a Fuzzy-Logic-based approach (SI Methods) to identify a common set of genes that was consistently up-, or, down-regulated in the PRLs of the compounds in the same community. We thus associated significant gene ontology (GO) terms to 57 communities by performing a GO enrichment analysis on the common set of genes (see online SI: <http://mantra.tigem.it>).

For example, in community n.3, mainly composed of cell cycle blockers (*Resveratrol*, *Ciclopirox*, *Etoposide*, *Deferoxamine*, *Kaempferol*, *Colforsin*, and *Quercetin*), the most enriched GO terms associated to down-regulated genes in this community were cell cycle process (p value 2.31×10^{-13}), mitotic cell cycle (p value

1.12×10^{-12}), and M phase (p value 1.49×10^{-10}). These terms are strictly related to the MoA shared by the drugs in this community. Other examples are reported in SI Methods.

We then assessed the opposite tendency, i.e., whether compounds characterized by the same MoA end up in the same community. We considered in the set of 804 compounds with known MoA (i.e., with an ATC code or a known target gene) a subset of 698 drugs. This subset contained only the drugs sharing their MoA with at least another drug and was divided in 429 groups (not mutually disjointed) of drugs with the same MoA (SI Methods). We verified that the MoA of 512 drugs (out of 698) was enriched for a specific community (p value < 0.05). This number goes up to 586 drugs, considering those with a significant odds ratio greater than 1 (Dataset S1 and online SI Fig. 9).

Prediction of Drug Mode of Action. We assessed the ability of the DN to predict the MoA of anticancer compounds whose gene expression profiles were not included in the original cMap dataset. As summarized in Fig. 1C, we measured expression profiles derived from different cell lines treated with anticancer compounds still being studied developed at Nerviano Medical Sciences (NMS) and reference drugs already present in the cMap dataset. Nine compounds were considered for a total amount of 39 microarray hybridizations. We computed a PRL for each of the tested compounds, and their distances from the 1,309 drugs in the cMap dataset. We then integrated the compounds in the DN by connecting them to the other drugs, if their distance was below the significant threshold (Fig. 3). Additionally, we computed a “drug-to-community” distance (SI Methods), which quantifies how close the tested compound is to each of the communities. This distance was defined as the weighted geometric average of the distances between the tested compound and the drugs belonging to the same community. The most similar compounds and the closest communities in the DN are provided in Table S1 and Dataset S1 for each of the tested compounds.

We tested three HSP90 inhibitors: *Tanespimycin* (already present in the cMap, used as control), the second-generation HSP90




Fig. 3. Classification of drugs. Subnetworks connected to the tested compounds (cyan nodes) once they have been integrated in the drug network. For clarity we included only compounds whose distances from the tested compounds were less than 0.8 (A and C) or 0.72 (B). Edge thickness is inversely proportional to the distance between the drugs; edge and node colors indicate communities. Hexagonal-shaped nodes represent community exemplars. (A) HSP90 inhibitors; (B) Topo inhibitors; (C) CDK inhibitors.

inhibitors *NVP-AUY922* (29) and *NMS-E973* (30). *Tanespimycin* is close to all four HSP90 inhibitors present in the database, as well as, to the protein synthesis inhibitor *Puromycin*, and to the proteasome inhibitors *Withaferin A* and *Parthenolide*; a similar list was also obtained for *NVP-AUY922* and *NMS-E973*. Fig. 3A shows the position of the three compounds in the DN. The closest community to the three tested compounds is n. 28, composed by the HSP90 inhibitors present in cMap, as well as the antiestrogen drug *Fulvestrant*, known to bind the estrogen receptor, dissociate HSP90, and trigger its intracellular degradation. The second closest community common to all the three compounds (n. 40) is enriched for proteasome inhibitors, ubiquitin proteasome system modulators (*Celastrol*, *MG-132*, *MG-262*, *Thapsigargin*, *Disulfiram*, *Mometasone*), and protein synthesis inhibitors (*Puromycin* and *Primaquine*). Another interesting surrounding community is n. 104, which contains the proteasome/NF- κ B inhibitors *Withaferin A*, *Parthenolide*, *Thiostrepton*, and *Etacrynic acid*. Weaker edges connect two of the three tested compounds to community n. 63, consisting of Na^+/K^+ -ATPase membrane pump inhibitors. This proximity might be explained by the fact that inhibition of Na^+/K^+ -ATPases by cardiac glycosides has been shown to affect NF- κ B signaling (31). Fuzzy GO term enrichment analysis showed that genes involved in the response to unfolded proteins are up-regulated in community n. 28 and community n. 104, whereas community n. 40 is enriched for GO terms relative to endoplasmic reticulum overload and stress. Therefore, the DN approach correctly predicted, with multiple evidences, the MoA of the tested compounds by identifying them as HSP90 inhibitors.

We also tested four cyclin-dependent kinases (CDKs) inhibitors. CDKs are key regulators of cell cycle progression: CDK2 and CDK4 are responsible for phosphorylation of the Retinoblastoma (RB) protein, causing activation of the E2F transcription factor and transcription of genes involved in G1/S transition and initiation of DNA replication (32). Several CDK inhibitors are being developed as anticancer agents, including *Flavopiridol*, currently in Phase III clinical trials (33). The cMap includes a limited number of molecules associated with this MoA. Therefore, we sought to probe the DN with the transcriptional profile of *Flavopiridol*, as well as those of *PHA-690509*, *PHA-793887*, and *PHA-848125*, three ATP-competitive CDK inhibitors developed at NMS, with different selectivity profiles within the CDK family, which have completed Phase I clinical trials (34) (Table S2 reports a selectivity profile of the four CDK inhibitors). The closest neighboring drugs and communities in the DN to each of the tested compound are listed in Table S1. All four CDK inhibitors were positioned in the DN in close vicinity to community n. 14, which includes a mixture of CDK and Topoisomerase inhibitors,

altogether accounting for about 80% of this community (Fig. 3C). The other closest community was n. 32, also containing several CDK and/or Topoisomerase inhibitors, such as the CDK2 inhibitors *Chrysin*, *Harmine*, *Harmol*, and *Harmol*, the CDK2/Topo II inhibitor *Apigenin*, the CDK2/Topo I inhibitor *Luteolin*, and the Topo I inhibitors *Irinotecan* and *Skimmianine*.

The intermixing of CDK and Topoisomerase inhibitors in communities n. 14 and n. 32, as well as the identification of several Topoisomerase inhibitors as the closest neighbors of the CDK inhibitors, implies a similarity of their effects at the transcriptional level, despite their different intracellular protein targets. To confirm this transcriptional similarity, we probed the DN with in-house generated transcriptional profiles following treatment with *SN-38*, the active metabolite of *Irinotecan* (a prototypic Topo I inhibitor) and with *Doxorubicin* (a prototypic Topo II inhibitor). *SN-38* and *Doxorubicin* were positioned, as expected, close to communities n. 14 and n. 32, containing their counterparts in the database (Fig. 3B). The 10 closest neighbors for both compounds are found in Table S1 and include a mixture of CDK and Topo I or II inhibitors. Whereas most CDK inhibitors act by competitively binding to the ATP pocket of kinases, and given that Topo II uses ATP hydrolysis for its function, we verified that there was no direct biochemical inhibition of CDKs by *SN-38* and *Doxorubicin*, and that *Flavopiridol* was not able to interfere with the ATPase activity of Topo II (Fig. S2). Another possible way to induce functional inhibition of CDKs is through the induction of their universal inhibitor p21. Indeed, DNA damage induced by Topoisomerase inhibitors causes p21 up-regulation activating both p53-dependent and independent apoptosis (35, 36). We hypothesized that p21 inhibition of the endogenous CDKs, and in particular CDK2, elicited an effect on RB-mediated transcription and might thus explain the similarity at the gene expression level. To confirm this, we treated MCF7 cells for 6 h with *PHA-793887* (used as reference CDK inhibitor), *Doxorubicin*, or *SN-38*, at the same doses previously used, and analyzed the protein cell lysates by Western blot (WB). Following treatment with both Topoisomerase inhibitors, we observed induction of p21 resulting in inhibition of CDK2, as measured by decreased phosphorylation of the CDK2 substrates, RB and nucleophosmin (Fig. 4A). Although we cannot exclude that induction of other genes, such as p27, in addition to p21, may also contribute to this effect. It was recently proposed that *Camptothecin* treatment would directly inhibit CDK9 activity by disrupting its complex with the activating Cyclin T partner, inducing a functional effect similar to that observed after ATP-competitive inhibition of CDK9 by *Flavopiridol* (37). To test this hypothesis, we analyzed the protein cell lysates used in the previous experiment for inhibition of RNA polymer-




Fig. 4. Western blots (A) Western blot of total MCF7 cell lysates following 6-h treatment of MCF7 cells with *Doxorubicin* (Dx), *SN38*, and the CDK inhibitor *PHA-793887* (887). Induction of p21 coupled to decreased phosphorylation of the CDK2 substrates Retinoblastoma (Rb) and Nucleophosmin (NPM) by the Topo inhibitors Dx and *SN38*. (B) Evaluation of LC3 levels in human fibroblasts after treatment with drugs: (Rp, Rapamycin; HF, Fasudil; Tr, Trifluoperazine; 2D, 2-deoxy-D-glucose; NT, untreated). The experiments were performed in triplicate, and representative results are shown.

ase II, as measured by decreased phosphorylation of its carboxy-terminal domain and diminished MCL1 (myeloid cell leukemia sequence 1) levels. After treatment with *PHA-793887* (CDK7 inhibition $IC_{50} = 10$ nM; CDK9 inhibition $IC_{50} = 140$ nM), a decrease of phosphoserine 5, and to a minor extent also of phosphoserine 2, was detected and resulted in diminished levels of MCL1. However, no effect on RNA Polymerase II phosphorylation or MCL1 levels was observed after treatment with the Topo inhibitors, suggesting that this pathway was not affected (Fig. S3). Taken together, these data prove that the transcriptional effects observed with the Topo I and Topo II inhibitors are due to an (indirect) inhibition of CDK2 (and possibly other CDKs such as CDK4) mediated by p21 induction, highlighting a previously unreported similarity that provides a strong rationale for the DN classification results.

Prediction of Unique Clinical Applications for Known Drugs. The DN approach can be used to find candidates for drug “repositioning,” i.e., to identify unique clinical applications of well-known drugs. We focused on identifying drugs that could enhance autophagy, a key biological process involved in cancer and in infectious and neurodegenerative diseases (38).

To this end, we searched the DN for drugs similar to 2-deoxy-D-glucose (2DOG), a molecule that is known for its ability to induce autophagy (39). 2-deoxy-D-glucose was found in community n. 1, which contained, in increasing order of distance to 2DOG, *Fasudil*, *Sodium-phenylbutyrate*, *Tamoxifen*, *Arachidonyltrifluoromethane*, and *Novobiocin* (see Table S3). Note that, in this community, two drugs (2DOG and *Tamoxifen*) are known autophagy inducers (39, 40) and that *Fasudil* is the closest drug to 2DOG. In addition, by analyzing the distances of 2DOG from the other compounds in the network, independently of the community they belong to, we found that the closest compounds to 2DOG were, in order of similarity, *Fasudil*, *Thapsigargin*, *Trifluoperazine*, and *Gossypol* (the whole neighborhood is provided in Table S3). Of these, *Thapsigargin*, *Trifluoperazine*, and *Gossypol* are known inducers of autophagy (41–43).

Despite being a drug with a well-characterized MoA, *Fasudil* has never been previously linked to autophagy. To verify the effect of *Fasudil* on the induction of autophagic pathway, we evaluated the LC3-II levels in wild-type human fibroblasts treated with *Fasudil*, by WB with anti-LC3 antibody, a well-established assay for the activation of autophagy (44). We measured a marked increase in LC3-II levels in fibroblasts treated with *Fasudil* and *Trifluoperazine* identified by the DN, as well as, in cells treated with 2DOG and *Rapamycin*, two well-known inducers of autophagy (Fig. 4B). Immunostaining with LC3 antibody further confirmed the WB analysis, demonstrating a strong activation of autophagic degradation upon treatment with *Fasudil* (Fig. S4). The effect of *Fasudil* on autophagy enhancement was further confirmed in HeLa cells (Fig. S5).

Discussion

We developed a general procedure to predict the molecular effects and MoA of new compounds, and to find previously unrecognized applications of well-known drugs. We were able to exploit information hidden in the gene expression profiles following drug treatment to capture similarity in drug MoA. Previous attempts to use gene expression profiles following compound treatment in mammalian cells did not consider the variability in the transcriptional response to the compound due to cell-line effects, to different dosages, and to different experimental settings. Moreover, information embedded in the global structure of the network of similarities among drugs has not been fully exploited in the past. We removed unspecific effects by capturing the “consensus” transcriptional response to a compound across multiple cell lines and dosages. We then automatically extracted a gene signature for each compound and computed pairwise similarities between compounds using a gene signature-based approach.

We analyzed the resulting network to identify communities of drugs with similar MoA and to determine the biological pathways perturbed by these compounds. We remark that, differently from other methods, whose aim is to identify the specific drug substrates (2, 6), our approach also groups together compounds interacting with distinct members of the same pathway.

The DN can be used to infer the MoA and targeted pathways of anticancer compounds still being studied and to find candidates for “drug repositioning” (i.e., to suggest unique clinical application for well-known and approved drugs).

We correctly classified both known and previously undescribed HSP90 inhibitors. Interestingly, in addition to the HSP90 inhibitors present in the database (*Alvespimycin*, *Geldanamycin*, and *Monorden*), several drugs included in the top 10 closest neighbors for *Tanespimycin* and *NMS-E973* were connected to inhibitors of the proteasome/NF- κ B pathway, including *Disulfiram* (45), *Withaferin A* (46), and *Parthenolide* (47).

We also investigated the ability of the DN to classify well-known (*Flavopiridol*) and previously undescribed CDK inhibitors (*PHA-690509*, *PHA-793887*, and *PHA-848125*). These drugs were correctly classified as CDK inhibitors, distinct from the other kinase inhibitors in the database, and were also predicted to be very similar to Topoisomerase inhibitors. Although the induction of p21 by DNA damage-inducing agents was previously reported, here we showed that this is clearly detected at the transcriptional level, supporting the concept that gene modulations can be used as a biomarker to monitor the effect of DNA damage-inducing agents.

In addition, we experimentally verified a surprising prediction: *Fasudil* promotes cellular autophagy. Given the excellent safety profile, this newly recognized effect of *Fasudil* could be exploited for disorders due to protein misfolding, including neurodegenerative diseases.

The drug network can be useful for formulating hypotheses on the MoA of previously undescribed compounds by simply measuring multiple transcriptional responses in different cell lines. In addition, drug repositioning is the easiest way to find previously undescribed drug therapies for different conditions. We have shown that it is possible to find previously unrecognized MoAs of well-characterized drugs by simply looking for the drugs neighboring a drug of interest. In addition, by analyzing the PRLs associated to each drug in the network, we may identify the drug communities that consistently up-, or down-regulate a given set of genes, thus hinting to drug classes able to modulate a specific pathway of interest. The major limitation of our approach is in the limited number of compounds in the network. Because our approach is based on comparing how similar two drugs are, if a compound is not similar to any of the drugs in the network, no inference on its MoA or its biological effects can be done.

Moreover, for a compound having inconsistent effects on different cell lines (for example, due to a cell line with a mutated substrate–protein targeted by the compound) merging gene expression profiles from distinct cell lines may dilute the biological effects of the compound. Nevertheless, when no information on the drug MoA is available a priori, the best strategy is still to merge profiles from multiple cell lines. We have evidences, reported in the [online SI Table 5](#) and [SI Methods](#), that merging profiles coming from a sufficiently large, even if heterogeneous, pool of treated cell lines, provides a summary of the transcriptional response to the drug that can still be well classified by the DN.

We have made our approach publicly available as an online tool (<http://mantra.tigem.it>). The DN can be easily searched for a compound of interest, or queried with the transcriptional responses of a unique compound, thus providing a valuable tool to the research community.

Methods

Treatment with Test Drugs for Microarray Hybridizations. A2780 cell lines (human ovary adenocarcinoma) were treated with *Flavopiridol*, *PHA-848125*,

PHA-690509, and *PHA-793887*, whereas MCF7 cell lines (human mammary adenocarcinoma) were treated with *PHA-848125*, *PHA-793887*, *Tanespimycin*, *NVP-AUY922*, *NMS-E973*, *SN-38*, and *Doxorubicin*. The procedures following treatments and the data availability are exhaustively detailed in [SI Methods](#).

Treatments for Western Blot of Total MCF7 Cell Lysates and Evaluation of Autophagy. For the Western blot, MCF7 cells were treated with *PHA-793887*, *Doxorubicin*, or *SN-38* at a dose equal to 5 times the IC50 for 6 h. For autophagy evaluation, synchronized wild-type human fibroblasts were treated with the following drugs: *Fasudil dihydrochloride* (Sigma) 10 μ M, *Trifluoperazine* (Sigma) 1 μ M, and *2DOG* (Sigma) 100 μ M for 48 h. The procedures following treatments are exhaustively detailed in [SI Methods](#).

ACKNOWLEDGMENTS. The authors thank W. Pastori, A. Deponti, I. Fraietta, L. Radrizzani, G. Locatelli, S. Healy, G. G. Galli, N. Avanzi, D. Volpi, F. Roletto, R. Baldi, B. Valsasina, M. Ciomei, G. Fogliatto, G. Raiconi, M. Lauria, G. Diez-Roux, J. D. Wichard, G. Gambardella, and J. Lamb. This work was supported by Fondazione Telethon Grants TDDP51TELC and TCBP37TELC (to D.d.B. and N.B.P.) and by the Italian Bioinformatics Network grant of the Italian Ministry of Research (to D.d.B.).

1. Terstappen GC, Schlupen C, Raggiacchi R, Gaviraghi G (2007) Target deconvolution strategies in drug discovery. *Nat Rev Drug Discov* 6:891–903.
2. di Bernardo D, et al. (2005) Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. *Nat Biotechnol* 23:377–383.
3. Ambesi-Impombato A, di Bernardo D (2006) Computational biology and drug discovery: From single-target to network drugs. *Curr Bioinform* 1:3–13.
4. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology. *Bioinformatics* 25:2466–2472.
5. Hopkins AL (2008) Network pharmacology: The next paradigm in drug discovery. *Nat Chem Biol* 4:682–690.
6. Mani KM, et al. (2008) A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. *Mol Syst Biol* 4:169.
7. Gardner TS, di Bernardo D, Lorenz D, Collins JJ (2003) Inferring genetic networks and identifying compound mode of action via expression profiling. *Science* 301:102–105.
8. Hu G, Agarwal P (2009) Human disease-drug network based on genomic expression profiles. *PLoS One* 4(8):e5536.
9. Hughes TR, et al. (2000) Functional discovery via a compendium of expression profiles. *Cell* 102(1):109–126.
10. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ (2008) Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. *Cell* 135(4):679–690.
11. Lamb J (2007) The Connectivity Map: A new tool for biomedical research. *Nat Rev Cancer* 7(1):54–60.
12. Lamb J, et al. (2006) The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. *Science* 313:1929–1935.
13. Yang K, Bai H, Ouyang Q, Lai L, Tang C (2008) Finding multiple target optimal intervention in disease-related molecular network. *Mol Syst Biol* 4:228.
14. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. *Science* 321:263–266.
15. Li J, Zhu X, Chen JY (2009) Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. *PLoS Comput Biol* 5(7):e1000450.
16. Keiser MJ, et al. (2009) Predicting new molecular targets for known drugs. *Nature* 462:175–181.
17. Miller MA (2002) Chemical database techniques in drug discovery. *Nat Rev Drug Discov* 1:220–227.
18. Iorio F, Tagliaferri R, di Bernardo D (2009) Identifying network of drug mode of action by gene expression profiling. *J Comput Biol* 16:241–251.
19. McAuley JJ, Costa LF, Caetano TS (2007) Rich-club phenomenon across complex network hierarchy. *Appl Phys Lett* 91:084103.
20. Diaconis P, Graham R (1977) Spearman's footrule as a measure of disarray. *J R Stat Soc* 39:262–268.
21. Lin S, et al. (2010) Space oriented rank-based data integration. *Stat Appl Genet Mol Biol* 9:Article20.
22. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 102:15545–15550.
23. Frey BJ, Dueck D (2007) Clustering by passing messages between data points. *Science* 315:972–976.
24. Newman ME (2006) Modularity and community structure in networks. *Proc Natl Acad Sci USA* 103:8577–8582.
25. Pahor M, et al. (1994) Drug data coding and analysis in epidemiologic studies. *Eur J Epidemiol* 10(4):405–411.
26. Schwabe U (1995) *ATC-Code* (Wissenschaftliches Institut der AOK, Bonn, Germany).
27. Wishart DS (2008) DrugBank and its relevance to pharmacogenomics. *Pharmacogenomics* 9:1155–1162.
28. Seiler KP, et al. (2008) ChemBank: A small-molecule screening and cheminformatics resource database. *Nucleic Acids Res* 36(Database issue):D351–359.
29. Eccles SA, et al. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. *Cancer Res* 68:2850–2860.
30. Fogliatto G, et al. (2009) Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy. *American Association for Cancer Research—Annual Meeting Poster* 37 (Abstract #4685).
31. Yang Q, et al. (2005) Cardiac glycosides inhibit TNF- α /NF- κ B signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. *Proc Natl Acad Sci USA* 102:9631–9636.
32. Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. *Trends Biochem Sci* 30:630–641.
33. Senderowicz AM (1999) Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. *Invest New Drugs* 17:313–320.
34. Brasca MG, et al. (2009) Identification of N,1,4,4-tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. *J Med Chem* 52:5152–5163.
35. Abal M, et al. (2004) Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. *Oncogene* 23:1737–1744.
36. Liu W, Zhang R (1998) Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. *Int J Oncol* 12:793–804.
37. Amente S, Gargano B, Napolitano G, Lania L, Majello B (2009) Camptothecin releases P-TEFb from the inactive 75K snRNP complex. *Cell Cycle* 8:1249–1255.
38. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ (2007) Potential therapeutic applications of autophagy. *Nat Rev Drug Discov* 6:304–312.
39. Ravikumar B, et al. (2003) Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. *Hum Mol Genet* 12:985–994.
40. de Medina P, Silvente-Poirot S, Poirot M (2009) Tamoxifen and AEB5 ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. *Autophagy* 5:1066–1067.
41. Criollo A, et al. (2007) Regulation of autophagy by the inositol trisphosphate receptor. *Cell Death Differ* 14:1029–1039.
42. Lei X, et al. (2006) Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. *FASEB J* 20:2147–2149.
43. Ogata M, et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. *Mol Cell Biol* 26:9220–9231.
44. Mizushima N (2004) Methods for monitoring autophagy. *Int J Biochem Cell Biol* 36:2491–2502.
45. Cvek B, Dvorak Z (2008) The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? *Drug Discov Today* 13:716–722.
46. Yang H, Shi G, Dou QP (2007) The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from “Indian winter cherry”. *Mol Pharmacol* 71:426–437.
47. Hehner SP, Hofmann TG, Droge W, Schmitz ML (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF- κ B by targeting the I κ B kinase complex. *J Immunol* 163:5617–5623.